FATE Stock Forecast: Fate Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.01
−3.81% on the day

The median 12-month analyst price target for Fate Therapeutics, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 85 of 100 as at 18 Nov 2026 — inside the top quartile.

Market cap
$124.1M
Ticker Nerd rank
85/ 100
Median analyst target
$7.00
Analysts covering
11
Revenue$2.1M+9.2% y/y
Operating income−$31.1M
Net income−$30.2M
Free cash flow−$23.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−24.6%
1M
−45.7%
YTD
+3.1%
1Y
−3.8%
From 52W high
−67.5%
From 52W low
+3.1%
$0.98
$3.11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Fate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
85/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
79
Accruals
79
Revisions
78
Momentum
62
Quality
60
Issuance
60
Value
52
Volatility
26

Growth (79): Sales and profits are climbing, and climbing faster than before.

Volatility (26): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FATE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FATE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26FATEHigh $8.00Median $7.00Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
5
Buy
6
Hold
0
Sell
$2.50
Low
$7.00
Median
$8.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Nov 2026Wells FargoMaintainsEqual-Weight$3.50 → $3.00
27 Oct 2026WedbushReiteratesOutperform$7.00
14 Aug 2026Piper SandlerReiteratesOverweight$6.00 → $8.00
14 Aug 2026WedbushReiteratesOutperform$7.00
14 Aug 2026Wells FargoMaintainsEqual-Weight$2.50 → $3.50
8 June 2026HC Wainwright & Co.ReiteratesBuy$7.00
4 May 2026HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.UpgradeBuy—
27 Oct 2025NeedhamReiteratesHold—
27 Oct 2025WedbushUpgradeOutperform—
13 Aug 2025Wells FargoMaintainsEqual-Weight—
12 June 2025NeedhamReiteratesHold—
14 May 2025BairdMaintainsNeutral—
14 May 2025BarclaysMaintainsOverweight—
14 May 2025NeedhamReiteratesHold—
6 Mar 2025NeedhamReiteratesHold—
6 Mar 2025StifelMaintainsHold—
6 Mar 2025WedbushReiteratesNeutral—
6 Mar 2025Wells FargoMaintainsEqual-Weight—
19 Nov 2024NeedhamReiteratesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FATE.

Market Radar

This page is one stock. Monday covers all of them.

FATE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FATE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Fate Therapeutics, Inc. returned −3.8% against +9.2% for the S&P 500, dividends included.

FATE vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26FATES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FATE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
26.1×

Cheaper than 7% of US stocks

Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−67.8%

Higher than 18% of US stocks

Return on assets
−27.9%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fate Therapeutics, Inc. has a market value of $124.1M and an enterprise value of $59.4M.

  • Revenue in the twelve months to 30 June 2026: $6.5M. The latest quarter grew 9.2% year on year.

  • Net income over the same four quarters: −$126.0M, a −1941.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.05.

  • Free cash flow in the twelve months to 30 June 2026: −$105.7M.

  • Shares outstanding: 116.7M.

  • Fate Therapeutics, Inc. employs 161 people — $40K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

FATE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FATEFate Therapeutics, Inc.$124.1M85
CDXSCodexis, Inc.$123.7M40
ENGNenGene Therapeutics, Inc.$124.0M21
NRXPNRX Pharmaceuticals, Inc.$124.1M19
NTHINeOnc Technologies Holdings, Inc.$119.8M31
IMUXImmunic, Inc.$119.4M19
MGNXMacroGenics, Inc.$125.2M87

Take a look at FATE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Fate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about FATE

What is the FATE stock price forecast for 2026-2027?

The median 12-month analyst price target for Fate Therapeutics, Inc. is $7, with estimates ranging from $2.5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FATE stock a buy right now?

Of the 11 analysts covering Fate Therapeutics, Inc., 5 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fate Therapeutics, Inc. 85 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FATE?

As at 18 Nov 2026, Fate Therapeutics, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).

Will FATE stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts is $7, and Ticker Nerd's factor model ranks Fate Therapeutics, Inc. 85 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FATE stock forecast for 2030?

No analyst covering Fate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FATE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $8 over the next 12 months.

How has FATE stock performed over the past year?

Fate Therapeutics, Inc. returned -3.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fate Therapeutics, Inc. do?

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer (NK) cell and T-cell programs designed to address key limitations in traditional cell manufacturing.

Company

About Fate Therapeutics, Inc.

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer (NK) cell and T-cell programs designed to address key limitations in traditional cell manufacturing. Its portfolio centers on immuno-oncology and immuno-regulatory applications, with product candidates aimed at treating solid tumors, blood cancers, and autoimmune disorders. Fate Therapeutics also applies its cell programming approach to engineer synthetic controls of cell function and produce renewable master cell lines for scalable development. Headquartered in San Diego, California, Fate Therapeutics plays a specialized role in the advanced cell therapy market, where it supports the transition from donor-derived treatments to more standardized, engineered therapeutic products.

CEO Dr. Bahram Valamehr M.B.A., Ph.D. · 161 employees · United States · https://www.fatetherapeutics.com